Hyderabad, 24 February, 2024: BioAsia is born with a vision to enhance, enrich and encourage newer innovations, path-breaking discoveries and effective solutions in the biotechnology industry by offering a vibrant global platform for convergence of the key stakeholders – Biotech & Biopharma Companies, research institutions, academia, investors, service providers, policymakers, regulators, and analysts. BioAsia is focused in its efforts – to drive the growth of the industry by enabling an effective environment for fostering collaborations, JVs M&As; ensure knowledge and experience sharing by global industry players to benefit all stakeholders; promote innovations and initiatives through appropriate awards and recognitions; play a pivotal role in advocating issues to the policymakers and chartering the road-map of biotechnology. BioAsia is a dynamic platform for companies -to exhibit, launch and showcase their unique strengths, products, and services. BioAsia is playing the role of a key catalyst in mobilizing all elements that are required to drive the growth of the emerging industry of Biotechnology as well as optimize the immense business potential of biotech. On a larger level, BioAsia is working to drive a global transformation from the treatment of illness to wellness.
The pandemic has brought into sharp focus the critical need for industry, academia, governments, regulators, and other stakeholders in the ecosystem to intensify their collaboration for ensuring healthcare innovation at scale and delivery with equitable access. In this context, the 21st edition of BioAsia – the marquee healthcare and Life Sciences event, organized by the Government of Telangana, will feature prominent government dignitaries, industry leaders, researchers, entrepreneurs, and other delegates, and explore the theme of Advancing for ONE: Shaping the next generation of humanized healthcare. The event is scheduled to be held between February 26 and 28, 2024 at the Hyderabad International Convention Center (HICC) in Hyderabad. Ernst and Young will be the knowledge partner of the event.
Moving back to a in-person format, Asia’s largest life-sciences and healthcare forum BioAsia 2024, will witness the participation of some of the most renowned and influential global leaders including:
Prof. Gregg Semenza – Nobel Laureate & Professor at Johns Hopkins School of Medicine
Mr. David Ricks – CEO, Eli Lilly and Company
Dr. Christopher Boerner – CEO, Bristol Myers Squibb
Mr. Geoff Martha – Chairman and CEO, Medtronic
Dr. Rodney Hochman – CEO, Providence
Mr. Stefan Kaufmann – CEO, Olympus
Mr. Jeremy Jurgens – Managing Director WEF & Head of the Forum’s C4IR & Head of Forum’s C41R
Dr. Arunish Chawla IAS – Secretary, Department of Pharmaceuticals, Government of India
Dr. Nitin Kumar Jain – Scientist ‘G’ & Member-Secretary, Department of Biotechnology, Review Committee on Genetic Manipulation (RCGM)
Dr. Vinod K. Paul – Member, NITI Aayog, Government of India
Dr. Sarah McMullen – Country Director – India, FDA
Mr. GV Prasad – Managing Director & Co-chairman, Dr Reddy Laboratories
Mr. Satish Reddy – Chairman, Dr Reddy Laboratories
Dr. Satyanarayana Chava – CEO, Laurus Labs
Dr. Sharvil Patel – Managing Director, Zydus Cadila
Mr. Toon Overstijns -Managing Director, Chairman of the Board, Miltenyi Biomedicine
Dr. D Nageshwar Reddy – Chairman & Managing Director, AIG Hospital
Dr. Ajit Shetty – Chairman VIB ( Flemish Institute of Biotechnology )
Dr. Gagandeep Kang – Director-Enterics, Diagnostics, Genomics and Epidemiology, Global Health
Mr. Jonathan Hunt – CEO & Managing Director, Syngene
Mr. Manni Kantipudi – CEO, Aragen Lifesciences
Mr. Christoph Koenen – Global Head of Clinical Development & Operations, Bayer
Prof. Alan Rowan – Director, Australian Institute for Bioengineering and Nanotechnology, University of Queensland
Mr. Robert Stanley – Global Head Intellectual Property and Legal Innovation, Head Legal, Internation, Norvatis among many others.
The inaugural day (27th Feb 2024) will hold three keynote address by each by Dr. Christopher Boerner, CEO, Bristol Myers Squibb; Prof. Gregg Semenza, Nobel Laureate & Professor Johns Hopkins,School of Medicine – Genome Valley Award; and Dr. Rodney Hochman, President & CEO, Providence.
The first panel discussion on 27th February will be on ‘Now or never – Pushing the boundaries to become global drug discovery engine’ involving eminent speakers viz., Mr. GV Prasad, Managing Director & Co-Chairman, Dr Reddy’s Laboratories; Dr. Sharvil Patel, Managing Director, Zydus Cadila; Mr. Toon Overstijns, Managing Director, Chairman of the Board, Miltenyi Biomedicine; Prof. Alan Rowan, Director, Australian institute for Bioengineering and Nanotechnology, University of Queensland; Prof. Rahul Purwar, Associate Professor, IIT Bombay and CEO & Founder, Immuno ACT; Dr. Sanjeev Panchal, Country President & Managing Director, AstraZeneca India; and the session will be moderated by Dr. Ajit Shetty, Chairman VIB (Flemish Institute of Biotechnology), Former Chairman of Janssen Pharmaceuticals.
A second panel discussion on ‘Perception vs. Reality: Navigating India’s IP Landscape in Drug Discovery’ will involve noted speakers viz., Mr. Robert Stanley, Global Head Intellectual Property and Legal Innovation, Head Legal, International ad interim, Novartis; Mr. Sudarshan Jain, Secretary General, IPA India; Mr. Pravin Anand, Managing Partner, Anand and Anand; Mr. Samir Kazi, Executive Vice President and Head of Legal, Compliance and Intellectual Property,Glenmark Pharmaceuticals Limited; Mr. Christoph Koenen, Global Head of Clinical Development & Operations, Bayer;Ms. Leena Menghaney, IP Advisor and Head, Medicines Sans Frontiers, South Asia; Mr. Taranpreet Lamba, Vice President and Head, Portfolio Planning & IP Litigation, Sun Pharma with moderator being Ms Anju Ghangurde, Executive Editor (Asia Pacific), Scrip.
‘Pushing Access to Medicines: Rationalizing the Regulatory Landscape for Vaccines and Biologics’ will be the third panel discussion with distinguished speakers viz., Mr. Sai Prasad, Executive Director, Bharat Biotech International Ltd; Mr. Sanjiv Navangul, Managing Director and CEO, Bharat Serums & Vaccines; Dr. K Anand Kumar, Managing Director, Indian Immunologicals Ltd; Mr. Gary Dubin, President, Global Vaccine Business Unit, Takeda Pharmaceuticals International AG; Dr Lokesh Jain, Scientist DBT; Dr. G.V.J.A. Harshavardhan, Director General, IVMA; Mr. Harshet Jain, General Manager, Business Development, Panacea Biotec Ltd with session moderation by Mr. Vikas Dandekar, Editor – Pharma & Life Sciences – ET Prime.
The fourth panel discussion on ‘Pharma Services: Navigating the path to global eminence in the CRO and CDMO landscape’ will have Mr. Jonathan Hunt, CEO & Managing Director, Syngene; Mr. Manni Kantipudi, CEO, Aragen Lifesciences; Mr. Sauri Gudlavalleti, COO, Sai Lifesciences; Mr. Akhil Ravi, Chief Executive Officer, Aurigene Pharmaceutical Services; Mr. Anil Matai, Director General, OPPI India; Mr. Giuliano Perfetti, CEO & Managing Director, Jubilant Biosys Ltd as the key speakers and the moderator will be Mr. Suresh Subramanian, Partner & National Life Sciences Leader, EY.
A CEO Conclave on ‘Geopolitical imperatives to reorganize the global drug supply chains: How did India fare vs. its potential and ambition’ will host prominent speakers viz., Mr. Satish Reddy, Chairman, Dr. Reddy’s Laboratories; Mr. Stefan Stoffel, Global Operating Partner, Advent; Dr. Satyanarayana Chava, CEO, Laurus Labs; Ms. Meenakshi Nevatia, Country President & Managing Director, Pfizer India; Ms. Nandini Piramal, Chairperson, Piramal Pharma Ltd; with the moderator being Ms. Ekta Batra, Anchor & Associate Editor Research, CNBC-TV18.
Day 3 of BioAsia on 28 February will also witness Launch of WEF C4IR Telangana, Govt. of Telangana and Mr. Jeremy Jurgens, Managing Director WEF & Head of the Forum’s C4IR. This will be followed by keynote address each by Mr. David Ricks, CEO, Eli Lilly; and Mr. Geoff Martha, Chairman & CEO, Medtronic.
The panel discussions will begin with the first topic being ‘Leading the Health-tech revolution – The Next Normal’ with key speakers Mr. Diogo Rau, EVP, Chief Information and Digital Officer, Eli Lilly and Company; Mr. Greg Meyers, EVP, Chief Digital and Technology Officer, BMS; Ms. Sangita Reddy, Joint Managing Director, Apollo Hospitals (India); Mr. Phanimitra, Chief Digital & Information Officer, Dr Reddy’s Laboratories; Mr. Scott Burgett, Director – Health Engg. Garmin; Mr. Sriram Rajamani, Corporate Vice President & Managing Director, Microsoft Research India; with Moderator being Mr. Jeremy Jurgens, Managing Director, World Economic Forum & Head of the Forum’s C4IR.
A second panel discussion on the day three will be ‘Unlocking the Potential of GCCs: From Centers Of Capability to Catalysts Of Global Transformation’ including important speakers Mr. Siva Padmanabhan, MD and Head, Global Innovation and Technology Centre, AstraZeneca; Mr. Manoj Prasad, VP, GM and Head of Digital Solutions APAC, Thermo Fisher Scientific; Ms. Mrinal Duggal, Head of Sanofi Global Services, Hyderabad Hub, Sanofi; Ms. Vani Kodandaram, Head of IT Culture and Strategy, Bristol Myers Squibb; Mr. Sanjay Vyas, EVP, Global SBU Head and Managing Director India, Parexel; with the Moderator being EY Partner – Sunil Venkatesh, Partner, Tech Consulting.
The third panel discussion on ‘TMedTech is the place to be! Tech and AI – The Powerful Combination for Medical Devices’ will host leading speakers Chair : Dr. Arunish Chawla IAS, Secretary, Department of Pharmaceuticals, Government of India; Co-Chair : Dr. D Nageshwar Reddy, Chairman & Managing Director, AIG Hospital; Dr. Sarah McMullen, Country Director – India, FDA; Dr. Gagandeep Kang, Director-Enterics, Diagnostics, Genomics and Epidemiology, Global Health, Bill and Melinda Gates Foundation; Mr. Probir Das, Group Executive Officer, Regional Representative, Asia Pacific and India, Chairman and Managing Director, Terumo Asia Holdings Pte. Ltd, Terumo; Mr. Andre Roggan, Executive Officer & Chief Technology Officer, Olympus; Dr. Mani Prakash, VP, Enterprise R&D, Medtronic; Mr. Rajiv Nath, Forum Coordinator, Association Of Indian Medical Device Industry and the session will be moderated by Mr. Ramesh Subrahmanian Non-Executive Independent Director-Healthium Medtech.
The conference will close with Valedictory and Startup award ceremony.
Commenting on the presence of the Lifesciences industry at BioAsia 2024, Mr. Sridhar Babu, Minister for Industries and Commerce, Government of Telangana, expressed his enthusiasm for the partnership said, “This is a very exciting time for both Telangana and India, going by the amount of innovation we are brinigng at the forefront. BioAsia’s 21st edition is a catalyst of bringing industry leaders together, exchange ideas, bring innovation and make Hyderabad the capital of life sciences in the world.”
“Parnterships, data-driven innovation and accelerating research with AI are at the core of BioAsia this time, and we are very happy to see such a turnout and such emiment people from the industry willing grow through knowledge transfer and bringing value addition to research and innovation,” said Mr. Jayesh Ranjan, IAS, Principal Secretary, Industries & Commerce Dept., Government of Telangana.
“Better access to healthcare and predictive medicine have been the call for many in the current times. Data and AI are going to be the main drivers of BioAsia this year. How best we can apply the use of Data and AI and the key take aways from the stellar speakers is something we are looking forward to. We are extremely thrilled with the extraordinary line-up of speakers, which is a testament to BioAsia’s growing repute,” said Mr. Shakthi Nagappan, Director of Life Sciences, Govt. of Telangana and CEO of BioAsia.
BioAsia’s influence extends globally, with past editions attracting several Nobel Prize winners, Lasker Awardees, and eminent industry leaders. BioAsia 2023 witnessed participation from over 3000 global participants from 50+ countries, setting the stage for an even more impactful BioAsia 2024.
Over the years, the event has immensely benefitted from its participant history including the likes of several Nobel Prize winners, Lasker Awardees and eminent industry leaders like Mr. Bill Gates (Chair, Gates Foundation), Mr. Satya Nadella (CEO of Microsoft), Mr. Alex Gorsky (Executive Chairman, Johnson & Johnson), Dr. Vas Narasimhan (CEO, Novartis), Mr. Geoff Martha (Chairman & CEO, Medtronic), besides hosting the Country Ministers and Delegates from Asia, America, Africa, and Europe. Being the first edition post pandemic, BioAsia 2023 was extremely successful with the virtual participation of more than 3000 global participants from over 50+ Countries.
